Kevin Raidy is the Managing Partner of Cowen Healthcare Investments. Mr. Raidy is currently a member of the Board of Directors of Escient Pharmaceuticals, NodThera Ltd., Aro Biotherapeutics, Neuron23, and is a Board Observer for Evox Therapeutics. Mr. Raidy previously served as a Board Member or Observer of PGDx, Semma Therapeutics, Repare Therapeutics, Pliant Therapeutics and Orchard Therapeutics.
Prior to his role at Cowen Healthcare Investments, Mr. Raidy was Cowen’s Head of Investment Banking and prior to that he served as co-head of Cowen’s equity capital markets group, which is responsible for the origination and execution of all equity capital-raising transactions. Before that, Mr. Raidy was a managing director at Cowen Investment Management (formerly known as Ramius LLC), where he was portfolio manager for direct investments and convertible bonds. Mr. Raidy also was the founder of H4 Capital Management LLC.
Mr. Raidy’s sell-side experience includes ten years at Shipley Raidy Capital Partners LP, a boutique investment banking firm that he co-founded, where he was responsible for sourcing, evaluating, and structuring numerous debt and equity financings and performed M&A advisory services.
Prior to founding Shipley Raidy, Mr. Raidy was an associate at Philadelphia First Group. He started his career at Cantor Fitzgerald before moving to Merrill Lynch as an analyst in the municipal finance group.
Mr. Raidy holds a BS in Economics with a concentration in finance from the Wharton School of the University of Pennsylvania.